

24<sup>th</sup> April 2025

**Change of OTC Ticker**

**Vitasora Health Limited** (ASX:VHL; OTCQB:RSHUF) ("**Vitasora**"), an eHealth Company supporting respiratory healthcare and Connected Care Management in the USA, refers to its ASX announcement of 22 April 2025 confirming its Change of Company Name and ASX Ticker.

Vitasora is pleased to confirm that the Company's OTC ticker symbol is in the process of being updated, with trading expected to commence under **VHLUF (OTCQB:VHLUF)** from 24 April 2025.

**- ENDS -**

**For further information, investors and media please contact:**

**Mr Marjan Mikel**

CEO & Managing Director

Vitasora Health Limited

P: +61 408 462 873

E: [marjan@vitasorahealth.com](mailto:marjan@vitasorahealth.com)

**Mr Nicholas Smedley**

Chairman

Vitasora Health Limited

P: +61 447 074 160

E: [nicholas@vitasorahealth.com](mailto:nicholas@vitasorahealth.com)

***This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.***

---

**About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider**

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at [www.vitasorahealth.com.au](http://www.vitasorahealth.com.au)

**About the wheezo® Medical Device**

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respi<sup>ri</sup>™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respi.co/us/> or for [wheezo®](https://wheezo.co/)

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

### **Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.